Press Room

Press Clipping / May 11, 2020

Hovione helping out HSE and community groups with donations of hand sanitiser

Echo Live, May 11, 2020

A PHARMACEUTICAL company has donated hand sanitiser to the HSE as well as local organisations to help the fight against Covid-19.

Douglas GAA, camogie and ladies football clubs recently received a large donation of hand sanitiser for those that are helping out in their community during the pandemic.

Hovione is a contract pharmaceutical manufacturing company which helps bring new and off-patent drugs to market.

Hovione, based in Ringaskiddy, has been manufacturing in Cork for 11 years and has more than 60 years experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates.

Hovione employs more than 200 people in Cork and approximately 1,800 globally including Lisbon and Loures in Portugal; Macau in China and New Jersey in America.

Hovione initially began manufacturing hand sanitiser for the protection of team members on site with dispensers placed across the site.

Since then the demand for hand sanitiser grew in our external community. This lead Hovione to appoint a project team to bring the manufacturing of hand sanitiser to distribution, so that it was readily available for donation to help protect various facilities and institutions across Ireland.

Key dates: April 11 – first day of Manufacturing - 17 days after the project kicked off.

April 20 – First batch of hand sanitiser was collected for use at St Stephen’s Hospital, Glanmire.

A spokesperson for the companys said: "A special thanks to the Hovione’s Project team, Site Leadership Team, Manufacturing and Warehouse Teams for all they have done to help with this fight against Covid-19.

"A heartfelt thank you from all at Hovione must be given to the various suppliers who have helped us fight Covid-19 together - SciChem Laboratory Supplies, OCON Chemicals Ltd, Carbon Group, Quitmann O’Neill Packaging Ltd, Schuetz Packaging and South Coast Sales.

"To date Hovione have supplied 17,000 litres across Ireland to nursing homes, care facilities, charities and hospitals. Hovione are working closely with An Garda Síochána to safely distribute hand sanitiser to the HSE across Ireland with 11,000 litres of hand sanitiser collected from site recently.

"On an international scale Hovione are distributing hand sanitiser free across all of our sites to support the local communities of each country we manufacture in."

Chairman of Douglas GAA Club, Aidan O'Connor thanks Hovione for their generous donation to the various clubs.

Read the article published at EchoLive.ie

Hovione helping out HSE and community groups with donations of hand sanitiser | Hovione

Also in the Press Room

See All

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products. Read the full article at EuropeanPharmaceuticalReview.com

Press Clipping

European Pharmaceutical Review, 4 November 2025

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025

US-base manufacturing and the continued rise of peptides were among the key themes for CDMOs at CPHI Frankfurt 2025. Andrew Warmington reports. Hovione announced during this show that it has completed an initial $100 million investment phase in the expansion of its manufacturing footprint in East Windsor, New Jersey. The company was one of the first European CDMOs to set up in the US back in 2002. CEO Jean-Luc Herbeaux said that when he took over the role four years ago, Hovione's footprint in the US was limited and the site was reaching capacity limitations. (...) Read the full article on SpecChemOnline.com

Article

Speciality Chemicals, Nov./Dec. 2025

Coming to America - Drug Product Focus

Nov 01, 2025

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet. The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026. As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities. Read the full article at DCATvci.org

Press Clipping

DCAT Value Chain Insights, 30 October 2025